COPD and asthma devices, also known as pulmonary drug delivery devices, are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. It is the most advanced mode of drug administration in which the drug is directly delivered to the lungs to provide a systemic effect. COPD and asthma have significant shares in the global respiratory diseases market. According to the Global Initiative for Asthma (GINA), around 300 million people across the world suffer from asthma every year. COPD, being the 3rd leading cause for death, led to the death of 3 million people in 2013. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.
The world COPD and asthma devices market is expected to reach $41,355.2 million by 2022. The major factors driving the market growth include increasing awareness for respiratory diseases, such as asthma and emphysema, and rising incidence of respiratory diseases caused due to cigarette consumption. The growth of the market would be boosted due to increase in healthcare expenditure, growth in the use of automation in healthcare industry, and rapid adoption of advanced medical solutions. Currently, most of healthcare practitioners and pulmonary diseases specialists prefer a combination of a drug and a device, for instance inhaler and nebulizer, owing to its fast and effective outcome. However, the market growth could be hindered due to high cost associated with nebulizers, side effects occurring due to excessive dosage, and lack of awareness regarding drug inhalation.
The world COPD and asthma devices market is segmented based on product device type and geography. Based on the product device type, the market is segmented into inhalers and nebulizers. Inhalers segment is projected to grow at a CGAR of 5.3% during the study period. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). The nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. Based on geography, the market is categorized into North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed on the basis of respective countries. Within Europe region, Germany, France and U.K. accounted for more than 40% of market share in 2015.
The leading players profiled in this report include GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Philips Healthcare, 3M Health Care, Allied Healthcare Products, Inc., Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim, GF Healthcare Products, Omron Corporation, Smith Medicals, Lincare Holdings, Inc., and Baxter International.
KEY BENEFITS
COPD AND ASTHMA DEVICES MARKET SEGMENTATION
The COPD and asthma devices market is segmented based on product type and geography.
By Product Types
By Geography
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Primary research
1.4.2 Secondary Research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond what to expect by 2027
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top impacting factors
3.2.2 Top investment pockets
3.2.3 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of buyers (High)
3.3.2 Bargaining power of suppliers (Low to Moderate)
3.3.3 Threat of new entrants (Low)
3.3.4 Threat of substitutes (High)
3.3.5 Intense competitive rivalry
3.4 Value chain analysis
3.5 Market share analysis, 2015
3.6 Government regulations
3.6.1 COPD devices regulations in Europe and in the U.S.
3.6.2 COPD devices regulations in Asia-Pacific
3.7 Drivers
3.7.1 Daily exposure to environmental pollution
3.7.2 Increase in population susceptible to indoor air pollutants
3.7.3 Portability of the drug delivery devices
3.7.4 Increasing population of Active smokers
3.7.5 Rising government initiatives
3.8 Restraints
3.8.1 Increasing price competition and deterioration of material quality
3.8.2 Overall high cost of asthma treatment is a challenge for the patients
3.8.3 Incompetent reimbursement support
3.9 Opportunities
3.9.1 Patent expiration for blockbuster drugs
3.9.2 Soft Mist Inhalers (SMIs): future growth driver
CHAPTER 4 WORLD COPD AND ASTHMA DEVICES MARKET, BY PRODUCT TYPE
4.1 Inhalers
4.1.1 Drug powdered inhalers (DPIs)
4.1.1.1 Key market trends
4.1.1.2 Key growth factors
4.1.1.3 Market size and forecast
4.1.2 Metered dose inhalers (MDIs)
4.1.2.1 Key market trends
4.1.2.2 Key growth factors
4.1.2.3 Market size and forecast
4.1.3 Soft mist inhalers
4.1.3.1 Key market trends
4.1.3.2 Key growth factors
4.1.3.3 Market size and forecast
4.2 Nebulizers
4.2.1 Compressor nebulizers
4.2.2 Ultrasonic nebulizers
4.2.3 Mesh nebulizers
CHAPTER 5 WORLD COPD & ASTHMA DEVICE MARKET, BY GEOGRAPHY
5.1 Introduction
5.2 Market size and forecast
5.3 North America
5.3.1 Key market trends
5.3.2 Market size and forecast
5.3.3 U.S
5.3.3.1 Market size and forecast
5.3.4 Canada
5.3.4.1 Market size and forecast
5.3.5 Mexico
5.3.5.1 Market size and forecast
5.4 Europe
5.4.1 Key market trends
5.4.2 Market size and forecast
5.4.3 UK
5.4.3.1 Market size and forecast
5.4.4 France
5.4.4.1 Market size and forecast
5.4.5 Germany
5.4.5.1 Market size and forecast
5.4.6 Italy
5.4.6.1 Market size and forecast
5.4.7 Russia
5.4.7.1 Market size and forecast
5.4.8 Others European countries
5.4.8.1 Market size and forecast
5.5 Asia-Pacific
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.5.4 India
5.5.4.1 Market size and forecast
5.5.5 China
5.5.5.1 Market size and forecast
5.5.6 Japan
5.5.6.1 Market size and forecast
5.5.7 Australia
5.5.7.1 Market size and forecast
5.5.1 Others
5.5.1.1 Market size and forecast
5.6 LAMEA
5.6.1 Key market trends
5.6.2 Market size and forecast
5.6.3 Brazil
5.6.3.1 Market size and forecast
5.6.4 Argentina
5.6.4.1 Market size and forecast
5.6.5 Colombia
5.6.5.1 Market size and forecast
5.6.6 Saudi Arabia
5.6.6.1 Market size and forecast
5.6.7 Turkey
5.6.7.1 Market size and forecast
5.6.8 Others
5.6.8.1 Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1 Glaxosmithcline PLC
6.1.1 Company overview
6.1.2 Operating business segment overview
6.1.3 Business performance
6.1.4 Key strategies move and development
6.1.5 SWOT analysis
6.2 Novartis AG
6.2.1 Company overview
6.2.2 Operating business segment overview
6.2.3 Business performance
6.2.4 Key strategies and development
6.2.5 SWOT analysis
6.3 Merck & Company
6.3.1 Operating business segment overview
6.3.2 Business performance
6.3.3 SWOT analysis
6.4 Philips Healthcare (Division of Royal Philips Company)
6.4.1 Company overview
6.4.2 Business performance
6.4.3 Strategic moves and developments
6.4.4 SWOT analysis
6.5 AstraZeneca Plc.
6.5.1 Company overview
6.5.2 Operating business segment overview
6.5.3 Business performance
6.5.4 Strategic moves and developments
6.5.5 SWOT analysis
6.6 3M Healthcare
6.6.1 Company overview
6.6.2 Business performance
6.6.3 Strategy move and development
6.6.4 SWOT analysis
6.7 GF Health Products
6.7.1 Company overview
6.7.2 Strategic moves and developments
6.7.3 SWOT analysis
6.8 Sunovion Pharmaceuticals Inc.
6.8.1 Company overview
6.8.2 Operating business segment overview
6.8.3 Business performance
6.8.4 Strategic moves and developments
6.8.5 SWOT analysis
6.9 Smith Medicals, Inc.
6.9.1 Company overview
6.9.2 Business performance
6.9.3 SWOT analysis
6.10 Baxter International
6.10.1 Company overview
6.10.2 Operating business segment overview
6.10.3 Business performance
6.10.4 SWOT analysis
6.11 Boehringer Ingelheim GmbH
6.11.1 Company overview
6.11.2 Operating business segment overview
6.11.3 Business performance
6.11.4 Key strategies and developments
6.11.5 SWOT analysis
List of Figures
FIG. 1 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO, 2022-2027
FIG. 2 IMPACT ANALYSIS OF RAPID GROWTH SCENARIO, 20222027
FIG. 3 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO, 20222027
FIG. 4 TOP FACTORS IMPACTING WORLD COPD AND ASTHMA DEVICES MARKET, 20152022
FIG. 5 TOP INVESTMENT POCKETS OF WORLD COPD AND ASTHMA DEVICES MARKET, BY PRODUCT TYPES
FIG. 6 TOP WINNING STRATEGY IN COPD AND ASTHMA DEVICES MARKET, 20122016
FIG. 7 TOP WINNING STRATEGIES, BY APPLICATION, 20122016
FIG. 8 PORTERS FIVE FORCES ANALYSIS OF WORLD COPD AND ASTHMA DEVICES MARKET
FIG. 9 VALUE CHAIN ANALYSIS OF WORLD COPD AND ASTHMA DEVICES
FIG. 10 MARKET SHARE ANALYSIS OF COPD AND ASTHMA DEVICES MARKET, 2015 (%)
FIG. 11 COPD AND ASTHMA INCIDENCE IN GREAT BRITAIN, 2003-2013
FIG. 12 U.S. ASTHMA AND COPD DEVICES MARKET, 20152022 ($MILLION)
FIG. 13 CANADA COPD AND ASTHMA DEVICES MARKET, 20152022 ($MILLION)
FIG. 14 MEXICO COPD AND ASTHMA DEVICES MARKET, 20152022 ($MILLION)
FIG. 15 UK COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 16 FRANCE COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 17 GERMANY COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 18 ITALY COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 19 RUSSIA COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 20 REST OF EUROPEAN COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 21 INDIA COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 22 CHINA COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 23 JAPAN COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 24 AUSTRALIA COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 25 REST OF APAC COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
FIG. 26 BRAZIL COPD AND ASTHMA MARKET, 20152022 ($MILLION)
FIG. 27 ARGENTINA COPD AND ASTHMA MARKET, 20152022 ($MILLION)
FIG. 28 COLOMBIA COPD AND ASTHMA MARKET, 20152022 ($MILLION)
FIG. 29 SAUDI ARABIA COPD AND ASTHMA MARKET, 20152022 ($MILLION)
FIG. 30 TURKEY COPD AND ASTHMA MARKET, 20152022 ($MILLION)
FIG. 31 OTHERS COPD AND ASTHMA MARKET, 20152022 ($MILLION)
FIG. 32 GLAXOSMITHKLINE PLC, REVENUE 2013-2015 ($MILLION)
FIG. 33 GLAXOSMITHKLINE PLC, REVENUE BY GEOGRAPHY 2015 (%)
FIG. 34 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS, 2015 (%)
FIG. 35 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 36 NOVARTIS AG REVENUE 2013-2015 ($MILLION)
FIG. 37 NOVARTIS AG REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 38 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS, 2015 (%)
FIG. 39 SWOT ANALYSIS OF NOVARTIS AG
FIG. 40 MERCK & CO. REVENUE, 2013-2015 ($MILLION)
FIG. 41 MERCK REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 42 MERCK REVENUE BY BUSINESS UNITS, 2015 (%)
FIG. 43 SWOT ANALYSIS OF MERCK
FIG. 44 PHILIPS REVENUE, 2013-2015, ($MILLION)
FIG. 45 PHILIPS REVENUE, BY BUSINESS UNITS, 2015 (%)
FIG. 46 SWOT ANALYSIS OF PHILIPS HEALTHCARE
FIG. 47 ASTRAZENECA INC REVENUE, 2013-2015 ($MILLION)
FIG. 48 ASTRAZENECA REVENUE, BY SEGMENT 2015 (%)
FIG. 49 ASTRAZENECA REVENUYE BY GEOGRAPHY, 2013 (%)
FIG. 50 ASTRAZENECA INC. SWOT ANALYSIS
FIG. 51 3M REVENUE, 2013-2015 ($MILLION)
FIG. 52 3M REVENUE BY BUSINESS SEGMENTS, 2015 (%)
FIG. 53 3M REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 54 SWOT ANALYSIS OF 3M
FIG. 55 SWOT ANALYSIS OF GF HEALTH PRODUCTS
FIG. 56 SUNOVION REVENUE, 2012-2015 ($MILLION)
FIG. 57 SUNOVION REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 58 SWOT ANALYSIS OF SUNOVION INC.
FIG. 59 SMITH MEDICAL INC. REVENUE, 2013-2015 ($MILLION)
FIG. 60 SMITH MEDICAL INC. REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 61 SMITH MEDICAL INC- SWOT ANALYSIS
FIG. 62 BAXTER INTERNATIONAL REVENUE, 2013-2015 ($MILLION)
FIG. 63 BAXTER INTERNATIONAL REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 64 BAXTER INTERNATIONAL REVENUE BY BUSINESS SEGMENTS, 2015 (%)
FIG. 65 SWOT ANALYSIS OF BAXTER INTERNATIONAL
FIG. 66 BOEHRINGER INGELHEIM REVENUE, 2013-2015 ($MILLION)
FIG. 67 BOEHRINGER INGELHEIM REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 68 BOEHRINGER INGELHEIM REVENUE BY BUSINESS SEGMENTS, 2015 (%)
FIG. 69 SWOT ANALYSIS OF BOEHRINGER INGELHEIM GMBH
List of Tables
TABLE 1 WORLD COPD AND ASTHMA DEVICES MARKET, MODERATE GROWTH SCENARIO BY GEOGRAPHY, 20222027 ($MILLION)
TABLE 2 WORLD COPD AND ASTHMA DEVICES MARKET, RAPID GROWTH SCENARIO BY GEOGRAPHY, 20222027 ($MILLION)
TABLE 3 WORLD COPD AND ASTHMA DEVICES MARKET, DIMINISHING GROWTH SCENARIO BY GEOGRAPHY, 20222027 ($MILLION)
TABLE 4 ADVANTAGES AND DISADVANTAGES OF MARKETED PORTABLE INHALER DEVICES
TABLE 5 PERCENTAGE OF SMOKER POPULATION BY ETHNICITY, 2012
TABLE 6 TOP 10 COUNTRIES HEALTHCARE EXPENDITURE, 2013
TABLE 7 WORLD COPD AND ASTHMA DEVICES MARKET, BY PRODUCT TYPE, 20152022, ($MILLION)
TABLE 8 RESCUE INHALERS VS MAINTENANCE INHALERS
TABLE 9 COMMON TYPES OF INHALERS
TABLE 10 TOP 10 COPD INHALERS
TABLE 11 WORLD COPD AND ASTHMA INHALERS MARKET, BY TYPE, 2015-2022, ($MILLION)
TABLE 12 WORLD COPD AND ASTHMA INHALERS MARKET, BY GEOGRAPHY, 2015-2022, ($MILLION)
TABLE 13 DRY POWDER INHALERS
TABLE 14 WORLD DRY POWDER INHALERS (DPI) MARKET, BY GEOGRAPHY, 20152022, $MILLION
TABLE 15 TYPES OF METERED DOSE INHALERS (MDIS)
TABLE 16 WORLD METERED DOSE INHALERS (MDI) MARKET, BY GEOGRAPHY, 20152022, $MILLION
TABLE 17 WORLD SOFT MIST INHALERS (SMI) MARKET, BY GEOGRAPHY,
TABLE 18 2015-2022, $MILLION
TABLE 19 COMMERCIALIZED NEBULIZERS AND ITS COST
TABLE 20 WORLD NEBULIZERS MARKET, BY TYPE, 20152022, ($MILLION)
TABLE 21 WORLD NEBULIZERS MARKET, BY GEOGRAPHY, 2015-2022, ($MILLION)
TABLE 22 WORLD COMPRESSOR NEBULIZERS MARKET, BY GEOGRAPHY, 2015-2022, ($MILLION)
TABLE 23 WORLD ULTRASONIC NEBULIZERS MARKET, BY GEOGRAPHY, 20152022, ($MILLION)
TABLE 24 WORLD MESH NEBULIZERS MARKET, BY GEOGRAPHY, 20152022, ($MILLION)
TABLE 25 WORLD COPD AND ASTHMA DEVICES MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 26 NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY TYPE, 2015-2022 ($MILLION)
TABLE 27 EUROPE COPD AND ASTHMA DEVICES MARKET, BY TYPE; 20152022 ($MILLION)
TABLE 28 ASIA-PACIFIC COPD DEVICES MARKET, BY TYPE, 2015-2022 ($MILLION)
TABLE 29 LAMEA COPD AND ASTHMA MARKET, BY TYPE, 2015-2022 ($MILLION)
TABLE 30 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 31 GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
TABLE 32 NOVARTIS AG SNAPSHOT
TABLE 33 NOVARTIS AG OPERATING SEGEMENTS
TABLE 34 MERCK COMPANY SNAPSHOT
TABLE 35 MERCK OPERATING SEGEMENTS
TABLE 36 PHILIPS HEALTHCARE BUSINESS SNAPSHOT
TABLE 37 ASTRAZENECA INC. SNAPSHOT
TABLE 38 ASTRAZENACA INC. OPERATING SEGMENT OVERVIEW
TABLE 39 3M SNAPSHOT
TABLE 40 GF HEALTH PRODUCTS SNAPSHOT
TABLE 41 SUNOVION SNAPSHOT
TABLE 42 SUNOVION OPERATING SEGEMENTS
TABLE 43 SMITH MEDICAL INC SNAPSHOT
TABLE 44 BAXTER SNAPSHOT
TABLE 45 BOEHRINGER INGELHEIM GMBH SNAPSHOT
TABLE 46 BOEHRINGER INGELHEIM GMBH OPERATING SEGEMENTS
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600